![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Monday, February 13, 2017 7:17:16 PM
This one covers several stocks but a number of his but others focus on just MSTX. The link to his list of blogposts: http://seekingalpha.com/author/leny-hettmansperger/instablogs
That said, I think he was propounding the thesis that the stock will rise to $.30 or so before the reverse split. I sure don't know what the ratio in the r/s will be, but it will have to be high enough to support uplisting the shares.
After the R/S, he was estimating the shares would grow sharply, once MSTX management is let go and the company is renamed Savara. They have two phase 2 studies ongoing on different drugs, a great relationship with the CF Foundation (which has provided non-dilutive funding) and a coorperative working relationship with the FDA.
I came into this as a long-time Savara shareholder (private as of now) with confidence in Savara management.
DISCLAIMER: All I say is just IMHO and does not construe investment advice. My wife informs me frequently that I know nothing and I say you should trust no one on the internet.
Greenlite Ventures Completes Agreement with No Limit Technology • GRNL • Jul 19, 2024 10:00 AM
VAYK Expects Revenue from First Airbnb Property Starting from August • VAYK • Jul 18, 2024 9:00 AM
North Bay Resources Acquires Mt. Vernon Gold Mine, Sierra County, California, with Assays up to 4.8 oz. Au per Ton • NBRI • Jul 18, 2024 9:00 AM
Nightfood Holdings Signs Letter of Intent for All-Stock Acquisition of CarryOutSupplies.com • NGTF • Jul 17, 2024 1:00 PM
Kona Gold Beverages Reaches Out to Largest Debt Holder for Debt Purchase Negotiation • KGKG • Jul 17, 2024 9:00 AM
Avant Technologies Welcomes Back Former CEO with Eye Toward Future Growth and Expansion • AVAI • Jul 17, 2024 8:00 AM